Endpoints News

Endpoints News

Ipsen makes another bet on blood cancer		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

Mon T W Th F

29 June, 2026

news

Zymeworks to acquire troubled biotech Theravance in $929M deal

Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront

Sobi receives CRL for gout combination drug over manufacturing

FDA approves Viridian's eye drug, stoking competition with Amgen's Tepezza

Jul 30

1:00 pm ET

Accelerating Phase 1 decisions with liquid biopsy: From early signals to actionable insights

sponsored by GUARDANT

Biopharma has metabolized the tariff chaos, but the ground keeps shifting under manufacturing and supply chain teams. Hear directly from the experts on what’s changed, what’s working, and what to watch. Join us.

PHARMA

FDA advisory panels are back, with new meetings for Replimune, Capricor

EU regulators recommend revoking the marketing authorization for Amgen’s Tavneos

EU probes Sanofi for alleged smear campaign against rival flu vaccine

in case you missed it

1.

Exclusive: Akeso pushes back on ASCO questioning of lung cancer drug

2.

Peer Review

Michael Gilman retires as Arrakis CEO; Daniel Skovronsky joins Illumina's board of directors

3.

After buying Apellis for $5.6B, Biogen is cutting most of its pipeline work

4.

How one biotech is using 'digital twins' to study a muscle disease therapy

5.

Lycia raises $75M for food allergy and Graves’ disease

6.

Internal EU document: Biotech Act has only limited impact

MedWatch

7.

What happens when you edit an essential gene in human embryos?

Chemical & Engineering News

Reynald Castaneda

.

We’re keeping a close eye on ESMO’s Gastrointestinal Cancer Congress, which kicks off Wednesday. If you have news to share, you can reach us here.

.

Reynald Castaneda

Deputy Editor, Endpoints News

2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com

Endpoints Studio
Endpoints Webinars

Endpoints Events
Biopharma Jobs

Worldwide made. Thanks for reading.